Piper Jaffray Hosts 22nd Annual Health Care Conference
NEW YORK, Nov 29, 2010 (BUSINESS WIRE) --
Piper Jaffray will host its 22nd annual Health Care Conference November 30 - December 1 in New York. Industry participants and investors will hear from more than 275 influential public and private companies in the biotechnology, specialty pharmaceuticals, drug discovery, medical technology, health care services, and medical diagnostics and devices sectors.
"Piper Jaffray has a longstanding commitment to the health care industry," said Jeff Klinefelter, director of research at Piper Jaffray. "Interest is particularly high in this year's conference given the macroeconomic environment and uncertainties associated with pending changes to health care in America as legislated by Congress."
The 22nd annual Piper Jaffray Health Care Conference will feature the industry's leading senior management teams presenting to an audience of nearly 1,500 attendees, including top institutional investors, equity portfolio managers and research analysts from the United States, Canada, the United Kingdom, Asia and Europe.
Featured companies include: 3SBio Inc.; Abaxis Inc.; ABIOMED, Inc.; AccessClosure, Inc.; Accuray Incorporated; Acorda Therapeutics, Inc.; Addex Pharmaceuticals Sa; Advanced BioHealing, Inc.; Advisory Board Co.; Affymax, Inc.; Affymetrix, Inc.; Agendia B.V.; Agennix AG; Akorn Inc.; Albany Molecular Research Inc.; Alder Biopharmaceuticals Inc.; Alexion Pharmaceuticals, Inc.; Algeta ASA; ALGETA NO; Allergan Inc.; Alliance HealthCare Services; Allscripts Healthcare Solutions, Inc.; Alnylam Pharmaceuticals, Inc.; Alphatec Holdings, Inc.; Amedica Corporation; American Medical Systems Holdings, Inc.; Anadys Pharmaceuticals, Inc.; AngioScore, Inc.; AngioSlide, Ltd.; Animal Health International, Inc.; Anthera Pharmaceuticals, Inc.; Antisoma plc; Ardea Biosciences; Arena Pharmaceuticals, Inc.; Array BioPharma, Inc.; ArthroCare Corporation; Athersys, Inc.; AtriCure, Inc.; Atritech, Inc.; Avantis Medical Systems, Inc.; AVEO Pharmaceuticals, Inc.; BÂRRX Medical, Inc.; Basilea Pharmaceutica; Baxter International Inc.; Beckman Coulter, Inc.; Becton, Dickinson and Company; Benefitfocus.com, Inc.; BioDelivery Sciences International Inc.; BioHorizons, Inc.; BioMarin Pharmaceutical Inc.; bioMerieux; BioScrip, Inc.; BioVex, Inc.; Boston Scientific Corporation; Calistoga Pharmaceuticals, Inc.; Cameron Health, Inc.; CapSite; Cardica Inc.; Cardiome Pharma Corp.; Celator Pharmaceuticals, Inc.; Celgene Corporation; Cephalon, Inc.; Cepheid; Cerapedics, Inc.; Cerner Corporation; Chimerix, Inc.; China Kanghui Holdings; China Pharma Holdings, Inc.; Clinical Data, Inc.; CoAxia, Inc.; Computer Programs And Systems Inc.; Concord Medical Services Holdings Limited; CONMED Corporation; Constellation Pharmaceuticals, Inc.; Corcept Therapeutics Inc.; Covance Inc.; Covidien, Ltd.; CryoLife, Inc.; Curis Inc.; Cutera, Inc.; Cyberonics, Inc.; DexCom, Inc.; Dfine, Inc.; Diversified Clinical Services, Inc.; DURECT Corporation; DynaVox Inc.; E+ Healthcare, LLC; Enanta Pharmaceuticals, Inc.; Endologix Inc.; Endosense SA; EndoStim Inc.; Entellus Medical, Inc.; eResearchTechnology, Inc.; Exact Sciences Corporation; Exelixis, Inc.; GenMark Diagnostics, Inc.; Genomic Health, Inc.; Gen-Probe Incorporated; GI Dynamics, Inc.; Gilead Sciences, Inc.; GlobeImmune, Inc.; Greatbatch, Inc.; GW Pharmaceuticals; Hansen Medical, Inc.; Healthways, Inc.; HeartWare International Inc.; Hill-Rom Holdings, Inc.; HMS Holdings Corp.; Hospira Inc.; Hutchison MediPharma Ltd.; Ideal Image Development, Inc.; IDev Technologies, Inc.; Illumina, Inc.; Immucor, Inc.; Impax Laboratories, Inc.; Incyte Corporation; Infinity Pharmaceuticals, Inc.; InfraReDx, Inc.; Integra LifeSciences Holdings Corporation; IntegraMed America Inc.; Integrated Diagnostics Incorporated; Intercell AG; InTouch Technologies, Inc.; Intuity Medical, Inc.; IRIS International Inc.; iScience Interventional, Inc.; ISIS Pharmaceuticals Inc.; Technologies, Inc.; Jarvik Heart, Inc.; JenaValve Technology GmbH; Johnson & Johnson; K2M, Inc.; Kinetic Concepts, Inc.; Laboratory Corporation of America Holdings; LDR Holding Corporation; LipoScience Inc.; Lutonix Inc.; MacroGenics, Inc.; MAKO Surgical Corp; Marina Biotech, Inc.; Masimo Corporation; MedAssets, Inc.; Medidata Solutions, Inc.; Medivance, Inc.; MELA Sciences, Inc.; Merit Medical Systems, Inc.; Merrimack Pharmaceuticals, Inc.; Metabolex, Inc.; Micromet, Inc.; MicroPort Medical (Shanghai) Co. Ltd.; Mindray Medical International Limited; MonoSol Rx, Inc.; Morphosys AG; MWI Veterinary Supply, Inc.; Myrexis, Inc.; Nanosphere, Inc.; Napo Pharmaceuticals, Inc.; Neomend, Inc.; NeoVista, Inc.; Neurocrine Biosciences Inc.; Neuronetics, Inc.; New American Therapeutics, Inc.; NovaMed, Inc.; Novavax, Inc.; Novo Nordisk A/S; NuVasive, Inc.; Obagi Medical Products, Inc.; Omeros Corporation; Omnicell, Inc.; Omthera Pharmaceuticals, Inc.; OncoGenex Pharmaceuticals, Inc.; OpGen, Inc.; OptiMedica Corporation; Optovue Inc.; Orthovita Inc.; Osiris Therapeutics, Inc.; PAREXEL International Corporation; PatientKeeper, Inc.; Patterson Companies Inc.; PDI, Inc.; Peregrine Pharmaceuticals Inc.; Pharmaceutical Product Development, Inc.; PharmaNet, Inc.; POZEN, Inc.; Precision Therapeutics, Inc.; Quality Systems, Inc.; Reata Pharmaceuticals, Inc.; RedBrick Health Corporation; Regado Biosciences, Inc.; Regeneron Pharmaceuticals Inc.; Regulus Therapeutics, LLC; ResMed Inc.; Revance Therapeutics, Inc.; Rib-X Pharmaceuticals, Inc.; Rigel Pharmaceuticals; Roche Holding AG; Rockwell Medical Technologies Inc.; Salient Surgical Technologies, Inc.; Salix Pharmaceuticals, Ltd.; Santarus Inc.; SciClone Pharmaceuticals, Inc.; Seattle Genetics Inc.; SkinMedica, Inc.; Somaxon Pharmaceuticals, Inc.; Sonitus Medical, Inc.; Sonoma Orthopedic Products, Inc.; St. Jude Medical, Inc.; Stentys S.A.S.; Steris Corp.; Stryker Corp.; Sucampo Pharmaceuticals, Inc.; superDimension, Ltd.; Symetis SA; Symmetry Medical Inc.; TEI Biosciences, Inc.; Tekmira Pharmaceuticals Corp.; Tengion, Inc.; Tetraphase Pharmaceuticals, Inc.; Theravance Inc.; Thoratec Corporation; Tolerx, Inc.; TomoTherapy Incorporated; TranS1 Inc.; Trident USA Health Services; Trius Therapeutics, Inc.; TYRX, Inc.; U.S. Preventive Medicine, Inc.; USGI Medical, Inc.; Valeant Pharmaceuticals International; Vapotherm, Inc.; Varian Medical Systems Inc.; Variation Biotechnologies, Inc.; VaxInnate, Inc.; VCA Antech, Inc.; Vertex Pharmaceuticals Inc.; Vertos Medical, Inc.; ViroPharma Inc.; Vital Images, Inc.; Volcano Corporation; Wright Medical Group, Inc.; WuXi AppTec Inc.; XDx, Inc.; ZIOPHARM Oncology, Inc.; ZONARE Medical Systems, Inc.
Company and investor participation in the Piper Jaffray Health Care Conference is by invitation only. Clients interested in attending should contact their Piper Jaffray representative. General and research-related media inquiries should be directed to AnalystMediaRelations@pjc.com. Investment banking-related media inquiries should be directed to Carol Osnes at email@example.com.
About Piper Jaffray
Piper Jaffray Companies (NYSE: PJC) is a leading, international investment bank and institutional securities firm, serving the needs of corporations, private equity groups, public entities, nonprofit clients and institutional investors. Founded in 1895, Piper Jaffray provides a broad set of products and services, including equity and debt capital markets products; public finance services; financial advisory services; equity and fixed-income institutional brokerage; equity research and fixed income analytics; and asset management services. Piper Jaffray headquarters are located in Minneapolis, Minnesota, with offices across the U.S. and in London and Hong Kong. Piper Jaffray & Co. is the firm's principal operating subsidiary. (www.piperjaffray.com)
Since 1895. Member SIPC and FINRA.
© 2010 Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, Minnesota 55402-7020
SOURCE: Piper Jaffray Companies